We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Neutralizing potency of COVID‐19 vaccines against the SARS‐CoV‐2 Omicron (B.1.1.529) variant.
- Authors
Lippi, Giuseppe; Mattiuzzi, Camilla; Henry, Brandon M.
- Abstract
Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variant The recent emergence of a new variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) called Omicron (B.1.1.529) has raised paramount concerns in scientific and medical communities due to the presence of several mutations in the spike protein, many of which are located within the receptor-binding domain (RBD).1 Some of these mutations were found to have a substantial influence on host cells receptors and anti-SARS-CoV-2 antibodies binding,2 which may then impact infectivity and neutralizing antibodies escape, thus potentially magnifying the risk of coronavirus disease 2019 (COVID-19) vaccine breakthrough. In all studies, the COVID-19 vaccine booster doses were effective to elicit a sustained enhancement of SARS-CoV-2 Omicron B.1.1.529 neutralization, with such increase being comprised between 3- and 133-folds compared to the pre-booster period (Table 1).
- Subjects
SARS-CoV-2 Omicron variant; SARS-CoV-2; COVID-19 vaccines; COVID-19; ADENOVIRUS diseases; TITERS
- Publication
Journal of Medical Virology, 2022, Vol 94, Issue 5, p1799
- ISSN
0146-6615
- Publication type
Article
- DOI
10.1002/jmv.27575